Cardiovascular function in acromegaly.
暂无分享,去创建一个
[1] J. Hardy,et al. Long‐term outcome and mortality after transsphenoidal adenomectomy for acromegaly , 2003, Clinical endocrinology.
[2] P. Chanson,et al. Guidelines for acromegaly management. , 2002, The Journal of clinical endocrinology and metabolism.
[3] P. Marzullo,et al. Early vascular alterations in acromegaly. , 2002, The Journal of clinical endocrinology and metabolism.
[4] A. Neskovic,et al. High output heart failure in patients with newly diagnosed acromegaly. , 2002, The American journal of medicine.
[5] R. Erbel,et al. Acromegaly: evidence for a direct relation between disease activity and cardiac dysfunction in patients without ventricular hypertrophy , 2002, Clinical endocrinology.
[6] C. Mady,et al. Treatment of acromegaly improves myocardial abnormalities. , 2002, American heart journal.
[7] P. Marzullo,et al. Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. , 2002, European journal of endocrinology.
[8] R. Clayton,et al. Endothelial dysfunction in endocrine disease , 2001, Trends in Endocrinology & Metabolism.
[9] R Erbel,et al. Occurrence of ventricular late potentials in patients with active acromegaly , 2001, Clinical endocrinology.
[10] P. Robbins,et al. Demonstration of Direct Effects of Growth Hormone on Neonatal Cardiomyocytes* , 2001, The Journal of Biological Chemistry.
[11] Y. Saitoh,et al. Characterization of premature atherosclerosis of carotid arteries in acromegalic patients , 2001, Clinical endocrinology.
[12] P. Marzullo,et al. Increased arterial intima‐media thickness by B‐M mode echodoppler ultrasonography in acromegaly , 2001, Clinical endocrinology.
[13] P. Marzullo,et al. Growth hormone and the heart , 2001, Clinical endocrinology.
[14] P. Chanson,et al. Vascular reactivity in acromegalic patients: preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction , 2000, Clinical endocrinology.
[15] F. Casanueva,et al. Criteria for cure of acromegaly: a consensus statement. , 2000, The Journal of clinical endocrinology and metabolism.
[16] B. Saul,et al. Clinical significance of variability of ventricular late potentials detected before discharge in patients after myocardial infarction. , 2000, American heart journal.
[17] P. Marzullo,et al. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. , 2000, The Journal of clinical endocrinology and metabolism.
[18] B. Biondi,et al. The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Cardiovascular Effects of Short-Term Growth Hormone , 2022 .
[19] M. Zamboni,et al. Body fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesity , 1999, International Journal of Obesity.
[20] T. Anderson,et al. Assessment and treatment of endothelial dysfunction in humans. , 1999, Journal of the American College of Cardiology.
[21] M. Salvatore,et al. Impact of patient's age and disease duration on cardiac performance in acromegaly: a radionuclide angiography study. , 1999, The Journal of clinical endocrinology and metabolism.
[22] F. Crea,et al. Cell death in acromegalic cardiomyopathy. , 1999, Circulation.
[23] R. Ross,et al. Atherosclerosis is an inflammatory disease. , 1998, American heart journal.
[24] L. Evans,et al. Heterogeneous haemodynamics in acromegaly: evidence of endothelial dysfunction? * , 1998, Clinical endocrinology.
[25] A. Simon,et al. Decreased regional blood flow in patients with acromegaly , 1998, Clinical endocrinology.
[26] P. Black,et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. , 1998, The Journal of clinical endocrinology and metabolism.
[27] R. McNally,et al. Mortality and Cancer Incidence in Acromegaly: A Retrospective Cohort Study , 1998 .
[28] A. Gulino,et al. Echocardiographic evidence for a direct effect of GH/IGF‐I hypersecretion on cardiac mass and function in young acromegalics , 1998, Clinical endocrinology.
[29] S. Coppack,et al. Endothelial Dysfunction: Cause of the Insulin Resistance Syndrome , 1997, Diabetes.
[30] S. Melmed,et al. New developments in the management of acromegaly , 1997 .
[31] R. Clayton. New developments in the management of acromegaly. Should we achieve absolute biochemical cure? , 1997, The Journal of endocrinology.
[32] L. Poston,et al. Oxidative Stress and Lipids in Diabetes: A Role in Endothelium Vasodilator Dysfunction? , 1996, Vascular Medicine.
[33] A. Baron,et al. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. , 1996, The Journal of clinical investigation.
[34] P. Douglas,et al. Differential cardiac effects of growth hormone and insulin-like growth factor-1 in the rat. A combined in vivo and in vitro evaluation. , 1996, Circulation.
[35] G. Molino,et al. Assessment of functional liver mass and plasma flow in acromegaly before and after long-term treatment with octreotide. , 1996, Metabolism: clinical and experimental.
[36] M. Radomski,et al. Nitric oxide--biological mediator, modulator and factor of injury: its role in the pathogenesis of atherosclerosis. , 1995, Atherosclerosis.
[37] P. Marzullo,et al. Growth hormone and the heart , 2001, Endocrine Updates.
[38] B. Biondi,et al. Impaired cardiac performance is a distinct feature of uncomplicated acromegaly. , 1994, The Journal of clinical endocrinology and metabolism.
[39] P. Wrightson,et al. Determinants of clinical outcome and survival in acromegaly , 1994, Clinical endocrinology.
[40] R. Clayton,et al. An audit of outcome of treatment in acromegaly. , 1993, The Quarterly journal of medicine.
[41] R. Dullaart,et al. Effect of a somatostatin analogue, octreotide, on renal haemodynamics and albuminuria in acromegalic patients , 1992, European journal of clinical investigation.
[42] R. Erbel,et al. Arrhythmia profile in acromegaly. , 1992, European heart journal.
[43] M. Komajda,et al. Cardiac hypertrophy and function in asymptomatic acromegaly. , 1991, European heart journal.
[44] J. Vane,et al. Regulatory functions of the vascular endothelium. , 1990, The New England journal of medicine.
[45] E. Raftery,et al. Subclinical cardiac dysfunction in acromegaly: evidence for a specific disease of heart muscle. , 1989, British heart journal.
[46] B. Sherman,et al. Variability in the quantitation of circulating growth hormone using commercial immunoassays. , 1989, The Journal of clinical endocrinology and metabolism.
[47] B. Bengtsson,et al. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. , 2009, Acta medica Scandinavica.
[48] R. Emanuel,et al. Acromegalic heart disease: influence of treatment of the acromegaly on the heart. , 1987, The Quarterly journal of medicine.
[49] J. Lie,et al. Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. , 1980, American heart journal.
[50] D. Appleton,et al. EPIDEMIOLOGY OF ACROMEGALY IN THE NEWCASTLE REGION , 1980, Clinical endocrinology.
[51] C. Lowy,et al. MORTALITY IN ACROMEGALY1 , 1970 .
[52] C. Lowy,et al. Mortality in acromegaly. , 1970, The Quarterly journal of medicine.
[53] C. Courville,et al. THE HEART IN ACROMEGALY , 1938 .